EXPERIENCE WITH THE ANTICOAGULANT, MARCUMAR
Authors: Robert E. Ensor, H. Raymond Peters
Journal: Annals of Internal Medicine (1957)

Article1 October 1957EXPERIENCE WITH THE ANTICOAGULANT, MARCUMARROBERT E. ENSOR, M.D., H. RAYMOND PETERS, M.D., F.A.C.P.ROBERT E. ENSOR, M.D.Search for more papers by this author, H. RAYMOND PETERS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-47-4-731 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAnticoagulant therapy is becoming increasingly important in the prevention and treatment of thrombo-embolic disease. Various investigators, in a search for an "ideal anticoagulant" have expressed preferences for one or the other of several drugs of this type which are available commercially or experimentally. Recently many investigators have favored phenindione (Hedulin) as the "anticoagulant of choice."1Among the anticoagulant drugs employed in our clinic since 1943 were bishydroxycoumarin (Dicumarol), cyclocumarol (Cumopyran), ethyl biscoumacetate (Tromexan ethyl acetate), phenindione (Hedulin), diphenadione (Dipaxin) and, more recently, phenprocoumon (Marcumar).†We were greatly impressed with the superiority of phenprocoumon with respect to greater predictability of results...Bibliography1. McCabeFittipoldi ESJ: Current status of use of phenyl-indanedione: case reports, Am. Pract. and Digest Treat. 4: 765, 1953. MedlineGoogle Scholar2. KollerJakob FH: Über ein neues, hochaktives Antikoagulans mit protrahierter Wirkung (Marcumar), Schweiz. med. Wchnschr. 83: 476, 1953. MedlineGoogle Scholar3. BourgainToddHerzigWright RMLI: Marcumar (3-(1′-phenyl-propyl)-4-hydroxycoumarin). A new anticoagulant, Circulation 10: 680, 1954. CrossrefMedlineGoogle Scholar4. BourgainToddSymonsHerzigWright RMCLI: A comparative study of Marcumar, Tromexan and Dicumarol, Schweiz. med. Wchnschr. 84: 820, 1954. MedlineGoogle Scholar5. Cosgriff SW: The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy, Ann. Int. Med. 45: 14, 1956. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Baltimore, Maryland*Received for publication November 14, 1956.From the Anticoagulant Clinic and Department of Medicine, Mercy Hospital Division, University of Maryland School of Medicine.Requests for reprints should be addressed to H. Raymond Peters, M.D., 1127 North Calvert Street, Baltimore 2, Maryland.†Marcumar Tablets, 3 mg., were supplied through the courtesy of Dr. Leo A. Pirk of Hoffmann-La Roche Inc., Nutley, New Jersey. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTherapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumonEvaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral AnticoagulationA COMPARATIVE STUDY CONCERNING THE STABILITY OF THE ANTICOAGULANT EFFECT OF ACENOCOUMAROL AND PHENPROCOUMONOrale AntikoagulantienFive-Year Study of Anticoagulants 1 October 1957Volume 47, Issue 4Page: 731-743KeywordsAnticoagulant therapyAnticoagulantsDrugsHemorrhageHospital medicineThrombosis ePublished: 1 December 2008 Issue Published: 1 October 1957 PDF downloadLoading ...